Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 58 Results

Title
Intervention Indication Therapeutic Area Year Actions
Durvalumab adjuvant therapy for treating hepatocellular carcinoma at high risk of recurrence after curative treatment Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Durvalumab and bevacizumab in addition to transarterial chemoembolisation for locoregional hepatocellular carcinoma Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2021 View  |  Download
Durvalumab for previously untreated,hepatocellular carcinoma Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2021 View  |  Download
Durvalumab in addition to gemcitabine and cisplatin for advanced biliary tract cancer – first line Cisplatin (Platinol) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Gemcitabine (Gemzar; gemcitabine hydrochloride) Biliary tract cancer Gastrointestinal Cancer 2021 View  |  Download
Durvalumab in combination with tremelimumab for unresectable hepatocellular carcinoma – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2019 View  |  Download
Durvalumab with bevacizumab adjuvant therapy for treating newly diagnosed hepatocellular carcinoma at high risk of recurrence after curative therapy Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Durvalumab with transarterial chemoembolisation for hepatocellular carcinoma Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Encorafenib in combination with binimetinib and cetuximab for BRAF V600E mutant metastatic colorectal cancer Binimetinib (MEK162; MEK-162; ARRY-162) , Cetuximab (Erbitux; STI-001) , Encorafenib (LGX818) Colorectal cancer Gastrointestinal Cancer , Oncology 2019 View  |  Download
Eryaspase in addition to chemotherapy for treating advanced or metastatic pancreatic cancer – second-line Eryaspase (Graspa; ERY001) , FOLFOX4 , Gemcitabine (Gemzar; gemcitabine hydrochloride) Pancreatic cancer Gastrointestinal Cancer 2020 View  |  Download
Infigratinib for unresectable locally advanced or metastatic cholangiocarinoma with FGFR2 rearrangements – second line Infigratinib (BGJ398; BGJ-398; Truseltiq) Cholangiocarcinoma Gastrointestinal Cancer 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications